On the basis of data from the phase III SOLAR-1 trial [114], the therascreen® PIK3CA RGQ PCR kit was granted FDA approval for the detection of PIK3CA mutations in plasma or tumor tissue in patients with advanced-stage (HR)+/HER2 − breast cancer. The gene discussed is PIK3CA; the disease is breast cancer.